Questions
Tournaments
Discover
Services
Questions
Tournaments
Discover
Questions
Tournaments
Questions
Questions
More
Log in
Sign Up
Log in
Sign Up
1
1 comment
Health & Pandemics
1 more...
Will the Phase 3 LiGeR-HN1 trial of petosemtamab + pembrolizumab in 1L HNSCC meet its primary endpoint before 2028?
Pre-Predict
Follow
share
embed
Revealed
in 3 days
Notify me when this resolves
Comments (1)
Key Factors (0)
Question Info
Similar Questions
No key factors yet
Add some that might influence this forecast.
Add key factor